MariTide (maridebart cafraglutide) by Amgen: status and timeline

MariTide (maridebart cafraglutide)

Long-acting GLP-1/GIP antagonist antibody-peptide conjugate, monthly injection. Phase 2: up to 20% weight reduction at 52 weeks in patients without Type 2 diabetes, up to 17% with Type 2 diabetes.

PilotStage 3 of 5

Phase 3 MARITIME for obesity and T2D. Readout early 2027. Also heart failure, kidney disease, sleep apnea.

Updated Mar 2025Checked 10 Oct0 updates this week

Milestones

Next · MARITIME-1 and MARITIME-2 primary readouts

Phase 2: 20% weight loss at 52 weeks (non-T2D), 17% with T2DNov 2024Complete.
MARITIME Phase 3 program initiatedMar 2025Complete.
MARITIME-1 and MARITIME-2 primary readoutsTarget Q1 2027Not yet reached.
Regulatory filing (if positive data)Target Q2 2027Not yet reached.

Most important updates

Upcoming

Q1 2027MARITIME-1 and MARITIME-2 primary readouts (next)
Q2 2027Regulatory filing (if positive data)

Current obstacles

Nausea and GI side effectsGLP-1 drugs cause nausea, vomiting and diarrhea in some patients, leading to discontinuation. Tolerability monitored in MARITIME.
Weight returns after stoppingWeight loss reverses quickly when dosing stops. Unclear if monthly dosing changes set point or just suppresses appetite.

Physics limits

Calorie suppression vs. thermogenesisGLP-1 drugs work primarily by reducing food intake. They do not increase metabolic rate, so maximal weight loss is limited by how much patients can comfortably eat less.
Gut hormone signaling has multiple targetsGLP-1 and GIP receptors are on many cell types (heart, kidney, pancreas). Activating them can improve glucose control and reduce inflammation, but can also cause side effects outside the appetite system.

How it works

3 parts

GLP-1 action

Slows stomach, signals fullness

MariTide activates GLP-1 receptors on the vagus nerve and in the brainstem, slowing gastric emptying and activating satiety centers.

GIP action

Blocks a second hunger pathway

By blocking GIP (a hormone that normally increases hunger after meals), it suppresses appetite via a second mechanism, adding to the GLP-1 effect.

Duration

Antibody recycling

Peptides conjugated to IgG2 antibody. Binds neonatal Fc receptor for recycling. Half-life ~150 days; monthly dosing.

Spec sheet

Spec	MariTide (maridebart cafraglutide)
Dosing frequency	Once monthly or less^R (reported)
Phase 2 weight reduction	Up to ~20% at 52 weeks (non-T2D), up to ~17% with T2D^R (reported)
Mechanism	GLP-1R agonist + GIP receptor antagonist (bispecific)^R (reported)

^R reported by the company

Update log

2 updates

Mar 2025

Major: Amgen initiates Phase 3 MARITIME program for MariTide across obesity, diabetes and heart failurePressTest

Nov 2024

Major: Amgen reports Phase 2 data: MariTide achieves up to 20% weight loss with monthly dosingPressTest

About Amgen

The team behind MariTide (maridebart cafraglutide)

Amgen

GLP-1 drugs, biopharmaceuticals, obesity, MARITIME trials

Founded 1980, Amgen is a biotech leader in recombinant DNA and GLP-1/GIP drugs. Headquartered in Thousand Oaks, California. Running Phase 3 MARITIME trials of MariTide for obesity and metabolic disease.

One of the world's largest biotech, $38.2B+ 2026 revenue guidance. Spans inflammation, cardiology, obesity, oncology.
MariTide, a monthly GLP-1/GIP agonist, in Phase 3 for obesity, T2D, heart failure, kidney disease. Readout early 2027.
Public since 1983 (AMGN), listed NASDAQ. CEO Robert Bradway since 2012.

amgen.com (opens amgen.com)Company profile →

Founded: 198046 yrs
Headquarters: United States
Status: Public
Valuation: $190Bmarket capJun 2026
Works in: BiotechObesity & metabolism
Coverage: 1 program · 3 updateslatest 30 Jun 2026checked 10 Oct
Partners: Roche (opens roche.com)
Suppliers: Eli Lilly (opens lilly.com)
People: Robert A. Bradway (opens amgen.com)CEO and ChairmanThomas Dittrich (opens amgen.com)Executive Vice President and Chief Financial Officer

Spec

MariTide (maridebart cafraglutide)

Dosing frequency

Once monthly or less^R (reported)

Phase 2 weight reduction

Up to ~20% at 52 weeks (non-T2D), up to ~17% with T2D^R (reported)

Mechanism

GLP-1R agonist + GIP receptor antagonist (bispecific)^R (reported)